PDCD1 and non-small cell lung carcinoma: In NSCLC patients, depending on the combination used, anti-programmed cell death protein-1 (PD-1) agents, given either alone or in combination with anti-cytotoxic T-lymphocyte antigen 4 (CLTA-4), irAEs were reported to occur in 10–80% [6] of ICI-treated patients.